TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05832892

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: surufatinib
Description: In phase Ib, surufatinib will be orally administrated 200 mg once a day (QD) or 250 mg QD per cohort escalation assignment on a 21-day cycle.~In phase II, surufatinib will be orally administrated at RP2D as determined in phase Ib.
Study: NCT05708924

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FT538
Description: FT538 IP at assigned dose level on Day 1, Day 8, and Day 15.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FT538
Description: FT538 IP at assigned dose level on Day 1, Day 8, and Day 15.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Enoblituzumab
Description: Enoblituzumab 15 mg/kg IV begin on Day -6 and continuing once every 3 weeks beginning on Day 22 until disease progression or unacceptable toxicity - refer to Section 7.2.1 for timing of the enoblituzumab dose on Day 22 if steroid pre-meds are needed due to an infusion reaction with the 1st enoblituzumab dose as there is a 14 day ban on corticosteroid use after the last dose of FT538
Study: NCT05832892

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KN046
Description: Nab-paclitaxel will be administrated at 125 mg/m2 intravenously on day 1 and 8 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: Gemcitabine will be administrated at 1000 mg/m2 intravenously on day 1 and 8 of each 21-day cycle.
Study: NCT05289128

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental group
Description: 10-sessions of anodal HD-tDCS ( tDCS 1x1, developed by Soterix Medical Inc.) associated to respiratory training; for 20 minutes (each session). It will be delivered a 3mA intensity electrical current accordingly 10/20 International System on cortical representation zone of left diaphragmatic motor cortex using HD-tDCS.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Control
Description: 10-sessions of anodal HD-tDCS( tDCS 1x1, developed by Soterix Medical Inc.) associated to respiratory training; for 20 minutes (each session) with a 3mA intensity.The device will provide a 30-second ramp-up followed immediately by a 30-second ramp down.
Study: NCT05442671

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Exercise intervention
Description: 16-week home exercise intervention, enriched by mobile health technology
Study: NCT06072495

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: real time MRI
Description: ubjects will be scanned in the supine position using ACHIEVA 3T TX DStream Philips® and a 33 channels head and neck coil. An elastic strap will be fixed to the forehead to limits movement during scan. Headset will be used to cancel the loud MRI noise and to communicate with the subjects
Study: NCT05832892

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: Nab-paclitaxel will be administrated at 125 mg/m2 intravenously on day 1 and 8 of each 21-day cycle.
Study: NCT04955067

Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnositic test
Description: The results of hip arthroscopy were taken as the gold standard, and MRI examination was taken as the research object

Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnositic test
Description: The results of hip arthroscopy were taken as the gold standard, and MRI examination was taken as the research object
Study: NCT05093998

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AV5080
Description: oral hard gelatin capsules

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Hard gelatin capsules with a white body
Study: NCT04800120

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hyperbaric Oxygen Therapy
Description: Delivery of 100% oxygen within a hyperbaric oxygen therapy chamber
Study: NCT05387577

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estradiol Tablets
Description: Oral estradiol will be taken sublingually, 1 mg BID for 8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Transdermal patch
Description: Estradiol patch therapy for 8 weeks
Study: NCT04955067

Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnositic test
Description: The results of hip arthroscopy were taken as the gold standard, and MRI examination was taken as the research object
Study: NCT05747274

Intervention type: DEVICE
Intervention: SRDK0921
Description: SRDK0921 is an IVD composed of IVD kit for qPCR (SRDK0921KIT) and a cloud-based software (SRDK0921SOFT). It is a class C, rule 3k, IVD according to Regulation (EU) 2017/746.
Study: NCT05745649

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance exercises
Description: Resistance exercises

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ankle weights
Description: Ankle weights
Study: NCT05171153

Intervention type: OTHER
Intervention: Densitometry with Trabecular Bone Score
Description: Conventional bone densitometry at the level of the proximal femur and lumbar spine (L1-L4) (anteroposterior and lateral) measured with a General Electric Prodigy Advance Full enCORE version 11.x equipment. With the data from the lateral densitometry, and using the VFA Dual Vertebral Assessment H8650DA/DM software, a quantitative morphometric analysis of the thoracolumbar vertebrae (T4-L4) will be carried out. Additionally, microarchitectural parameters of the lumbar spine will be evaluated with TBS (iNsight v3.0) and bone quality in the proximal femur with the DEXA-3D 3D-SHAPER v2.10.1 software. Vertebral fracture will be excluded from the DXA and TBS analysis of the spine.

Intervention type: OTHER
Intervention: Densitometry with Trabecular Bone Score
Description: Conventional bone densitometry at the level of the proximal femur and lumbar spine (L1-L4) (anteroposterior and lateral) measured with a General Electric Prodigy Advance Full enCORE version 11.x equipment. With the data from the lateral densitometry, and using the VFA Dual Vertebral Assessment H8650DA/DM software, a quantitative morphometric analysis of the thoracolumbar vertebrae (T4-L4) will be carried out. Additionally, microarchitectural parameters of the lumbar spine will be evaluated with TBS (iNsight v3.0) and bone quality in the proximal femur with the DEXA-3D 3D-SHAPER v2.10.1 software. Vertebral fracture will be excluded from the DXA and TBS analysis of the spine.

Intervention type: OTHER
Intervention: Quantitative Ultrasound of Calcaneus
Description: Quantitative bone ultrasound of calcaneus evaluated with a SONOST 3000, (OsteoSys Co, Korea).

Intervention type: OTHER
Intervention: Quantitative Ultrasound of Calcaneus
Description: Quantitative bone ultrasound of calcaneus evaluated with a SONOST 3000, (OsteoSys Co, Korea).

Intervention type: OTHER
Intervention: Laboratory test
Description: Analysis of general biochemical parameters and serum phospho-calcium metabolism, including: total calcium, albumin, phosphorus, 25-OH-vitamin D, intact PTH (iPTH), creatinine, estimated glomerular filtration rate, carboxy-terminal telopeptide of type I collagen ß-CTx (Crosslaps) and N-terminal propeptide of type I procollagen (P1NP).

Intervention type: OTHER
Intervention: Laboratory test
Description: Analysis of general biochemical parameters and serum phospho-calcium metabolism, including: total calcium, albumin, phosphorus, 25-OH-vitamin D, intact PTH (iPTH), creatinine, estimated glomerular filtration rate, carboxy-terminal telopeptide of type I collagen ß-CTx (Crosslaps) and N-terminal propeptide of type I procollagen (P1NP).
Study: NCT05547412

Intervention type: DEVICE
Intervention: NovaGuide 2 Intelligent Ultrasound System
Description: The NovaGuide 2 Intelligent Ultrasound system is an adjunctive mobile, non-invasive, non-ionizing radiation transcranial Doppler (TCD) diagnostic ultrasound system. The system contains a transcranial doppler ultrasound equipment combined with robotic mechanisms used to position ultrasound probes, which assist the user in the acquisition of cerebral blood flow velocity (CBFV) data via a patient's temporal acoustic windows.

Intervention type: DEVICE
Intervention: NovaGuide 2 Intelligent Ultrasound System
Description: The NovaGuide 2 Intelligent Ultrasound system is an adjunctive mobile, non-invasive, non-ionizing radiation transcranial Doppler (TCD) diagnostic ultrasound system. The system contains a transcranial doppler ultrasound equipment combined with robotic mechanisms used to position ultrasound probes, which assist the user in the acquisition of cerebral blood flow velocity (CBFV) data via a patient's temporal acoustic windows.

Intervention type: DEVICE
Intervention: NovaGuide 2 Intelligent Ultrasound System
Description: The NovaGuide 2 Intelligent Ultrasound system is an adjunctive mobile, non-invasive, non-ionizing radiation transcranial Doppler (TCD) diagnostic ultrasound system. The system contains a transcranial doppler ultrasound equipment combined with robotic mechanisms used to position ultrasound probes, which assist the user in the acquisition of cerebral blood flow velocity (CBFV) data via a patient's temporal acoustic windows.
Study: NCT06072495

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: real time MRI
Description: ubjects will be scanned in the supine position using ACHIEVA 3T TX DStream Philips® and a 33 channels head and neck coil. An elastic strap will be fixed to the forehead to limits movement during scan. Headset will be used to cancel the loud MRI noise and to communicate with the subjects

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: real time MRI
Description: ubjects will be scanned in the supine position using ACHIEVA 3T TX DStream Philips® and a 33 channels head and neck coil. An elastic strap will be fixed to the forehead to limits movement during scan. Headset will be used to cancel the loud MRI noise and to communicate with the subjects

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: real time MRI
Description: ubjects will be scanned in the supine position using ACHIEVA 3T TX DStream Philips® and a 33 channels head and neck coil. An elastic strap will be fixed to the forehead to limits movement during scan. Headset will be used to cancel the loud MRI noise and to communicate with the subjects
Study: NCT05700630

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FT538
Description: FT538 is an investigational off-the-shelf cryopreserved NK cell product derived from an iPSC that contains three functional modifications: 1) a novel high affinity, non-cleavable CD16 (Fc receptor) that maintains CD16 on the cell surface and remains fully functional after NK cell activation, thus augmenting ADCC; 2) an IL-15 receptor fusion that promotes NK cell activity and enhances cell persistence; and 3) the knock-out of CD38 expression prevent anti-CD38 antibody-induced fratricide.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FT538
Description: FT538 is an investigational off-the-shelf cryopreserved NK cell product derived from an iPSC that contains three functional modifications: 1) a novel high affinity, non-cleavable CD16 (Fc receptor) that maintains CD16 on the cell surface and remains fully functional after NK cell activation, thus augmenting ADCC; 2) an IL-15 receptor fusion that promotes NK cell activity and enhances cell persistence; and 3) the knock-out of CD38 expression prevent anti-CD38 antibody-induced fratricide.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Vorinostat is a histone deacetylase inhibitor (HDACi) that is FDA approved for the treatment of cutaneous T-cell lymphoma and, under investigation in HIV as disruptor of HIV latency.
Study: NCT05696847

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Administered SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study: NCT05634486

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multidisciplinary therapeutic approach (physiotherapy plus cognitive-behavioral therapy)
Description: Patients randomly allocated to this arm of intervention will receive an ambulatory therapy regime of twelve 60-minute physiotherapy sessions plus four 60-minute psychotherapy sessions throughout one month of treatment

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Psychoeducation (Sham intervention)
Description: Patients randomly allocated to this arm of intervention will receive an ambulatory regime of four 60-minute non-organized psychoeducational sessions throughout one month of treatment.
Study: NCT04141150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]APN-1607
Description: In this study, all patients will receive one injection of \[18F\]APN-1607, a PET radiopharmaceutical selective for fibrillar tau. For the injection, subjects will receive a target dose of 7 mCi IV as a bolus injection. \[18F\]APN-1607 injection will be followed by a 10 ml saline flush.
Study: NCT05512767

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Undergo self-manual lymphatic drainage

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Consensus Auditory-Perceptual Evaluation of Voice
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Consensus Auditory-Perceptual Evaluation of Voice
Description: Ancillary studies
Study: NCT05387577

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estradiol Tablets
Description: Oral estradiol 1 mg BID for 8 weeks
Study: NCT05806021

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone Acetonide
Description: Intra-articular injection. For each group, the total injected will be 3 ml. For syringes containing triamcinolone acetonide, the missing volume will be filled with 0.9% isotonic saline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Acetonide
Description: Intra-articular injection. For each group, the total injected will be 3 ml. For syringes containing triamcinolone acetonide, the missing volume will be filled with 0.9% isotonic saline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Acetonide
Description: Intra-articular injection. For each group, the total injected will be 3 ml. For syringes containing triamcinolone acetonide, the missing volume will be filled with 0.9% isotonic saline
Study: NCT05069285

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: self-help book
Description: information and advice given in the self-help book

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: sleep hygiene advice
Description: information and advice given on the sheet of paper with sleep hygiene
Study: NCT05855486

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Saline eye drops
Description: Ocular drops used to facilitate the removal of ocular secretions in pediatric subjects
Study: NCT06020001

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: AP203 mixture (RESCOVIN®)
Description: Polyphenol-rich plant extracts Twice a day

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: AP203 mixture (RESCOVIN®)
Description: Polyphenol-rich plant extracts Twice a day

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Twice a day
Study: NCT05515393

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XY03-EA
Description: The sample size was 420 patients, and 140 patients were treated with XY03-EA 300 mg, 600 mg and placebo respectively. The 300-mg group took two tablets of placebo and two tablets of XY03-EA once, three times a day. The 600-mg group took four tablets of XY03-EA once, three times a day. The placebo group took four tablets of placebo once ,three times a day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XY03-EA
Description: The sample size was 420 patients, and 140 patients were treated with XY03-EA 300 mg, 600 mg and placebo respectively. The 300-mg group took two tablets of placebo and two tablets of XY03-EA once, three times a day. The 600-mg group took four tablets of XY03-EA once, three times a day. The placebo group took four tablets of placebo once ,three times a day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: XY03-EA Placebo
Description: XY03-EA Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XY03-EA Placebo
Description: XY03-EA Placebo
Study: NCT05386498

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: precured composite insert technique
Description: After curing of bonding agent a 2mm increment of composite will be placed on the gingival floor of the cavity and cured. a measured volume of composite(3mm height and 2mm width) will be cured outside the oral cavity on a flat plastic instrument for 40 seconds. a second increment of composite will be placed on the cavity and the precured composite will be pressed in the uncured increment and pressed outward against the matrix band and light cured for 20 seconds the rest of the cavity will be filled using the oblique layering technique.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Contact making instrument
Description: a 1-2mm increment of the composite will be placed in the gingival floor of the proxial box.~a contact forming instrument will be placed in this uncured increment and an outward force will be applied using the instrument from the inside of the matrix band. The composite will then be cured for 20 seconds to achieve a tight contact.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Incremental composite layering technique
Description: Increments will be placed in 1-2mm increments in oblique layering manner by a flat plastic instrument and condenser .Each increment will be cured for 20 seconds till the cavity is slightly overfilled.
Study: NCT05032794

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Unrestricted diet before colonoscopy
Description: Free diet, without restrictions

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 1-day low residue diet
Description: To follow a diet low in residues / fiber. the day before the colonoscopy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bisacodyl 5 MG
Description: If the participant is at risk of inadequate bowel cleansing, defined by a score of Dik et al ≥ 2 it will be given Bisacodyl 5 milgrams bid for 3 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bisacodyl 5 MG
Description: If the participant is at risk of inadequate bowel cleansing, defined by a score of Dik et al ≥ 2 it will be given Bisacodyl 5 milgrams bid for 3 days.
Study: NCT06196177

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levosimontane injection
Description: Levosimendan injection was given once intravenously with a micro-pump: 12.5mg levosimendan injection was diluted with 5% glucose injection to 50ml at the initial pump speed of 2ml/h for 24h.
Study: NCT05868161

Intervention type: DEVICE
Intervention: Pounce Thrombectomy System
Description: Non-surgical removal of thrombi and emboli from the peripheral arterial vasculature with the Pounce Thrombectomy System.
Study: NCT05106946

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ThisCART22 cells
Description: 0.2-60 x 10\^6 CAR T cells per kg body weight
Study: NCT04530747

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin + PAP
Description: Subjects randomized to this arm will receive 500 mg capsules containing metformin extended release (XR). Metformin XR dosing will be 500 mg (1 x 500 mg) every evening (qPM) during Week 1, 1000 mg (2 x 500 mg) qPM during Week 2, 1500 mg (3 x 500 mg) qPM during Week 3, and 2000 mg (4 x 500 mg) qPM from Week 4 onwards.~Subjects will also be provided PAP (positive airway pressure) device for standard management of obstructive sleep apnea.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule + PAP
Description: Subjects randomized to this arm will receive 500 mg capsules containing placebo. Placebo dosing will be 500 mg (1 x 500 mg) qPM during Week 1, 1000 mg (2 x 500 mg) qPM during Week 2, 1500 mg (3 x 500 mg) qPM during Week 3, and 2000 mg (4 x 500 mg) qPM from Week 4 onwards.~Subjects will also be provided PAP (positive airway pressure) device for standard management of obstructive sleep apnea.
Study: NCT06449170

Intervention type: OTHER
Group type: OTHER
Intervention: Mango Ataulfo
Description: In this intervention, subjects consumed 150g of mango Ataulfo plus 150 ml of control beverage (Supportan® Drink Cappuccino). The addition of the control beverage has the purpose of providing energy intake and limiting the noise that the control beverage may contribute to the metabolomic profile in urine and serum.

Intervention type: OTHER
Group type: OTHER
Intervention: Avocado Hass
Description: In this intervention, subjects consumed 120g of avocado hass plus 150 ml of a control beverage (Supportan® Drink Cappuccino). The addition of the control beverage provides energy intake and limits the noise that the beverage may contribute to the metabolomic profile in urine and serum.

Intervention type: OTHER
Group type: OTHER
Intervention: Nopal
Description: In this intervention, subjects consumed 300g of cooked nopal and 150 ml of control beverage (Supportan® Drink Cappuccino). The addition of the control beverage provides energy intake and limits the noise that the beverage may contribute to the metabolic profile in urine and serum.

Intervention type: OTHER
Group type: OTHER
Intervention: 3 corn tortilla
Description: In this intervention, subjects consumed 3 corn tortillas and 150 ml of control beverage (Supportan® Drink Cappuccino). The addition of the control beverage provides energy intake and limits the noise that the beverage may contribute to the metabolic profile in urine and serum.

Intervention type: OTHER
Group type: OTHER
Intervention: Guava
Description: In this intervention, subjects consumed 3 guavas and 150 ml of control beverage (Supportan® Drink Cappuccino). The addition of the control beverage provides energy intake and limits the noise that the beverage may contribute to the metabolic profile in urine and serum.

Intervention type: OTHER
Group type: OTHER
Intervention: Amaranth
Description: In this intervention, subjects consumed 1/2 cup of amaranth and 150 ml of control beverage (Supportan® Drink Cappuccino). The addition of the control beverage provides energy intake and limits the noise that the beverage may contribute to the metabolic profile in urine and serum.

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Control Beverage (Supportan Drink ® Capuccino)
Description: In this intervention, subjects consumed 290ml of Supportan Drink ® Capuccino to act as a control for the metabolomic profiling in urine and serum.